RECRUITINGOBSERVATIONAL
Association Between LRG and Histologic Remission in Ulcerative Colitis
What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?
About This Trial
We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.
Who May Be Eligible (Plain English)
Who May Qualify:
- active UC patients
Who Should NOT Join This Trial:
- None
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* active UC patients
Exclusion Criteria:
* None
Locations (1)
Showa Inan General Hospital
Komagane, Japan